Zoladex, Goserelin Newswire

Zoladex, Goserelin Newswire

Comprehensive Real-Time News Feed for Zoladex, Goserelin (generic).

Results 1 - 20 of 21 in Zoladex, Goserelin (generic)

  1. Breast Cancer Treatment Ribociclib Wins Priority ReviewRead the original story

    Nov 1, 2016 | P&T Community

    The FDA has accepted the new drug application for ribociclib and has granted the drug priority review for the first-line treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer in combination with letrozole. The NDA was partly based on results from a phase 3 trial that showed that ribociclib plus letrozole reduced the risk of disease progression or death by 44% compared with letrozole alone , significantly extending progression-free survival .

    Comment?

  2. US Prostate Cancer Market Drug Forecast and Market Analysis to 2023Read the original story w/Photo

    Oct 19, 2016 | SBWire

    Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems.

    Comment?

  3. N.Y. considers puberty blockers for trans teensRead the original story w/Photo

    Oct 14, 2016 | Washington Blade

    Leuprolide , along with triptorelin and goserelin, are often used to delay puberty in transgender youth until they are old enough to begin hormone replacement therapy.

    Comment?

  4. Common prostate cancer treatment which shuts off the body's supply ...Read the original story w/Photo

    Oct 13, 2016 | Daily Mail

    Roughly 18,000 men in Britain start taking hormone pills or injections every year - nearly 40 per cent of the 47,000 men diagnosed with prostate cancer. The treatments work by lowering levels of testosterone, a hormone which is normally harmless but in prostate cancer patients can drive the growth of tumours.

    Comment?

  5. Prostate cancer sufferers who have hormone treatment 'double' their risk of dementiaRead the original story w/Photo

    Oct 13, 2016 | Mirror.co.uk

    Thousands of men who undergo hormone treatment for prostate cancer face double the risk of developing dementia, a study shows. Androgen Deprivation Therapy lowers the body's supply of testosterone and is a less drastic alternative to physical castration.

    Comment?

  6. A comparative study on the efficacies of gonadotropin-releasing...Read the original story w/Photo

    Aug 31, 2016 | BioMed Central

    Neoadjuvant androgen deprivation therapy has been suggested to confer several clinical benefits in patients with prostate cancer undergoing transperineal prostate brachytherapy . Unlike gonadotropin-releasing hormone receptor agonists, a GnRH antagonist such as degarelix can achieve castrate levels of testosterone without testosterone flare.

    Comment?

  7. Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA...Read the original story w/Photo

    Aug 3, 2016 | Drugs.com

    Novartis announced today that the US Food and Drug Administration has granted Breakthrough Therapy designation to LEE011 , in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase inhibitor.

    Comment?

  8. Ribociclib Receives Breakthrough Therapy Designation for Advanced Breast CancerRead the original story

    Aug 3, 2016 | P&T Community

    The FDA has granted breakthrough therapy status to ribociclib , in combination with letrozole, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Ribociclib is a selective cyclin-dependent kinase inhibitor.

    Comment?

  9. Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA...Read the original story w/Photo

    Aug 3, 2016 | Freshnews

    Novartis announced today that the US Food and Drug Administration has granted Breakthrough Therapy designation to LEE011 , in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase inhibitor.

    Comment?

  10. Temporary undernutrition during early gestation, corpora lutea...Read the original story

    May 26, 2016 | CSIRO Publishing

    P. Langendijk A C D , E. G. Bouwman A , T. Y. Chen A , R. E. Koopmanschap B and N. M. Soede B A South Australian Research and Development Institute, Roseworthy Campus, Roseworthy, SA 5371, Australia. B Adaptation Physiology Group, Wageningen University, PO Box 338, 6700 AH, Wageningen, The Netherlands.

    Comment?

  11. Why patients have no drugs at Uganda Cancer InstituteRead the original story w/Photo

    Jun 18, 2016 | Daily Monitor

    Kampala- Patients and doctors at the Uganda Cancer Institute have been reduced to living life on a thin thread of hope and despair. The UCI's authorities have had a protracted friction with the National Medical Stores for three years over inflated drug prices far above the local and international market rates.

    Comment?

  12. Platelet to lymphocyte ratio as an independent prognostic indicator...Read the original story w/Photo

    May 23, 2016 | BioMed Central

    Platelet to Lymphocyte ratio is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer patients receiving hormonal therapy.

    Comment?

  13. Novartis AG Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer's IbranceRead the original story

    May 18, 2016 | BioSpace

    MONALEESA-2 is a pivotal Phase III trial of LEE011 , a cyclin dependent kinase inhibitor , in combination with letrozole, compared to letrozole alone in postmenopausal women who had received no prior therapy for their hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer[1]. "We are excited that these results validate our belief that LEE011 in combination with letrozole can be a beneficial treatment option for women diagnosed with HR+/HER2- advanced breast cancer," said Alessandro Riva, Global Head, Oncology Development and Medical Affairs, Novartis Oncology.

    Comment?

  14. The role of the addition of ovarian suppression to tamoxifen in young ...Read the original story w/Photo

    May 19, 2016 | BioMed Central

    Ovarian function suppression has been shown to be effective as adjuvant endocrine therapy in premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit.

    Comment?

  15. Positive Efficacy Results Reported for Breast Cancer Drug RibociclibRead the original story

    May 18, 2016 | P&T Community

    The independent data monitoring committee for a pivotal phase 3 breast-cancer trial of ribociclib , a cyclin-dependent kinase inhibitor, has recommended stopping the trial early after results of a preplanned interim analysis showed that the study had met the primary endpoint of a clinically meaningful improvement in progression-free survival . The news puts ribocilcib on track to compete with Pfizer's blockbuster drug palbociclib , according to a Reuters report.

    Comment?

  16. Alvogen Launches First Generic Equivalent Of ZoladexRead the original story

    May 4, 2016 | BioSpace

    Alvogen today announced the launch of the first generic equivalent of ZoladexTM in Central and Eastern Europe. The product will be marketed in two strengths under the brand name ReseligoTM and will be launched in Bulgaria, Croatia, Baltics, Romania, Hungary, Iceland and Poland from May 2016.

    Comment?

  17. Alvogen Launches First Generic Equivalent of ZoladexRead the original story w/Photo

    May 5, 2016 | Business Wire

    The product will be marketed in two strengths under the brand name ReseligoTM and will be launched in Bulgaria, Croatia, Baltics, Romania, Hungary, Iceland and Poland from May 2016. Astra Zeneca's ZoladexTM, delivered sales of over EUR 200 million in Europe in 2015, according to IMS.

    Comment?

  18. UK fully supportive of complex pharma manufacturing, George Freeman MPRead the original story w/Photo

    Apr 28, 2016 | In-PharmaTechnologist.com

    The UK Government has recently pushed a number of pharma manufacturing incentives, from the tax-beneficial 'patent box' which saw GSK invest A 370m at a plant in Cumbria in 2012 , to the opening of a A 38m National Biologics Manufacturing Centre last year . Speaking at the Biotrinity Event in London this week, the UK's first minister for life science George Freeman MP said the Government is fully behind homegrown pharma and biopharma production, and cited Britain's complex manufacturing expertise as a differentiator.

    Comment?

  19. Metastatic breast cancer: AstraZeneca's Faslodex (fulvestrant) approved for new indication in the USARead the original story w/Photo

    Mar 7, 2016 | Medical News Today

    AstraZeneca has announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex to include use in combination with Ibrance . The combination use is for the treatment of women with hormone receptor-positive , human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer whose cancer has progressed following endocrine therapy.1 Fulvestrant has been approved in the US since 2002 and in Europe since 2004 as a monotherapy for the treatment of postmenopausal women with HR+ MBC whose cancer has progressed following antioestrogen therapy.

    Comment?

  20. Serial transvaginal ultrasound-guided biopsy of the porcine corpus luteum in vivoRead the original story

    Mar 2, 2016 | CSIRO Publishing

    S. BjA rkman A E , J. Yun B , M. Niku C , C. Oliviero A , N. M. Soede D and O. A. T. Peltoniemi A A Production Animal Hospital, Department of Production Animal Medicine, P.O. Box 66, 00014 University of Helsinki, Finland. B Research Centre for Animal Welfare, Department of Production Animal Medicine, P.O. Box 66, 00014 University of Helsinki, Finland.

    Comment?